Neuraura Biotech Inc

Neuraura operates at the intersection of medical devices, bioelectronics, neuromodulation, and women's health. Its differentiation is a targeted focus on PCOS and related metabolic and reproductive conditions rather than a broad consumer wellness offering. The company describes a proprietary micro-electrode platform designed for high-fidelity, low-noise biological signal recording and percutaneous stimulation, with wearable and potentially implantable applications. Its proposed market-entry strategy begins with pelvic pain and an FDA 510(k) pathway before expanding claims toward insulin resistance and other PCOS-related outcomes. That creates a staged regulatory and clinical strategy, but it also means the company's ultimate market position depends on evidence generation, clearance, reimbursement, and patient adherence. Relative to general digital health products, Neuraura appears more technically differentiated through hardware and stimulation capabilities. Relative to established neuromodulation and women's-health device makers, it remains an early-stage entrant with a small employee base, approximately $763,809 in recorded total funding, and no disclosed valuation or commercial scale.

Neuraura's trajectory shows a long early-development cycle supported by grants, accelerator assistance, and pre-seed financing rather than a conventional priced venture sequence. The company was founded in 2017 and received non-equity assistance from Creative Destruction Lab on Oct 1, 2017, followed by a $447,270 pre-seed round on Jun 1, 2018. Additional activity included a $261,357 pre-seed round in 2020, $55,182 in 2021, and later support from mHUB on Nov 12, 2024 and the Center of Aging and Brain Health Innovation on Mar 27, 2025. The founders—Claire Dixon, Colin Dalton, and Pierre Wijdenes—are recorded in leadership roles beginning in December 2022, while the current organization size remains in the 1–10 employee range. The main inflection point is the transition from proprietary micro-electrode development toward a defined LoOoP platform and a proposed regulatory entry through pelvic pain.